Mortality after diagnosis of psychiatric disorders and co-occurring substance use disorders among HIV-infected patients

AIDS Patient Care and STDs

Volumn 24, Issue 11, 2010, Pages 705-712

  Delorenze, Gerald N ^a   Satre, Derek D ^a,b   Quesenberry, Charles P ^a   Tsai, Ai Lin ^a   Weisner, Constance M ^a,b  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ANOREXIA; ARTICLE; BIPOLAR DISORDER; BULIMIA; COHORT ANALYSIS; COMORBIDITY; DEATH; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MORTALITY; PANIC; RETROSPECTIVE STUDY; RISK FACTOR; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; BIPOLAR DISORDER; CAUSE OF DEATH; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; HIV INFECTIONS; HUMANS; MALE; MENTAL DISORDERS; MENTAL HEALTH SERVICES; MIDDLE AGED; PANIC DISORDER; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 78149435685     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2010.0139     Document Type: Article

References (43)

1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998;280:1497-1503. (Pubitemid 28507402)
2. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug anti-retroviral regimens. CMAJ 1999;160:659-665. (Pubitemid 29149796)
3. Murphy EL, Collier AC, Kalish LA, et al. Highly active an-tiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26. (Pubitemid 32619279)
4. Nash D, Katyal M, Shah S. Trends in predictors of death due to HIV-related causes among persons living with AIDS in New York City: 1993-2001. J Urban Health 2005;82:584-600. (Pubitemid 41758606)
5. Fonseca MG, Lucena Fde F, Sousa A, Bastos FI. AIDS mor-tality, "race or color," and social inequality in a context of universal access to highly active antiretroviral therapy (HAART) in Brazil, 1999-2004. Cad Saude Publica 2007;23(Suppl 3):S445-455.
6. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006;145:397-406.
7. Woldemichael G, Christiansen D, Thomas S, Benbow N. Demographic characteristics and survival with AIDS: health disparities in Chicago, 1993-2001. Am J Public Health 2009;99(Suppl 1):S118-123.
8. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: A longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006;163:412-420.
9. Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and sub-stance use disorders in an HIV clinic in the Southeastern United States. J Acquir Immune Defic Syndr 2006;42:298-306. (Pubitemid 44050007)
10. Conigliaro J, Madenwald T, Bryant K, et al. The Veterans Aging Cohort Study: Observational studies of alcohol use, abuse, and outcomes among human immunodeficiency virus-infected veterans. Alcohol Clin Exp Res 2004;28:313-321. (Pubitemid 38233609)
11. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002;16:767-774.
12. Himelhoch S, Chander G, Fleishman JA, Hellinger J, Gaist P, Gebo KA. Access to HAART and utilization of inpatient medical hospital services among HIV-infected patients with co-occurring serious mental illness and injection drug use. Gen Hosp Psychiatry 2007;29:518-525. (Pubitemid 350088154)
13. Compton WM, Thomas YF, Stinson FS, Grant BF. Pre-valence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and re-lated conditions. Arch Gen Psychiatry 2007;64:566-576. (Pubitemid 46718289)
14. Rae AM, Joyce PR, Luty SE, Mulder RT. The effect of a history of alcohol dependence in adult major depression. J Affect Disord 2002;70:281-290. (Pubitemid 34786645)
15. Antelman G, Kaaya S, Wei R, et al. Depressive symptoms increase risk of HIV disease progression and mortality among women in Tanzania. J Acquir Immune Defic Syndr 2007;44:470-477. (Pubitemid 46555384)
16. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: Longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001;285:1466-1474. (Pubitemid 32221895)
17. Hessol NA, Kalinowski A, Benning L, et al. Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis 2007; 44:287-294. (Pubitemid 46079997)
18. French AL, Gawel SH, Hershow R, et al. Trends in mortality and causes of death among women with HIV in the United States: A 10-year study. J Acquir Immune Defic Syndr 2009;51:399-406.
19. Shacham E, Nurutdinova D, Satyanarayana V, Stamm K, Overton ET. Routine screening for depression: Identifying a challenge for successful HIV care. Aids Patient Care STDs 2009;23:949-955.
20. Pence BW. The impact of mental health and traumatic life experiences on antiretroviral treatment outcomes for people living with HIV/AIDS. J Antimicrob Chemother 2009;63: 636-640.
21. Kacanek D, Jacobson DL, Spiegelman D, Wanke C, Isaac R, Wilson IB. Incident depression symptoms are associated with poorer HAART adherence: A longitudinal analysis from the Nutrition for Healthy Living study. J Acquir Im-mune Defic Syndr. 2010;53:266-272.
22. Mkanta WN, Mejia MC, Duncan RP. Race, outpatient mental health service use, and survival after an AIDS diagnosis in the highly active antiretroviral therapy era. Aids Patient Care STDs 2010;24:31-37.
23. Walley AY, Cheng DM, Libman H, et al. Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. AIDS. 2008;22:415-420.
24. Burnam MA, Bing EG, Morton SC, et al. Use of mental health and substance abuse treatment services among adults with HIV in the United States. Arch Gen Psychiatry 2001;58: 729-736. (Pubitemid 32717796)
25. Himelhoch S, Brown CH, Walkup J, et al. HIV patients with psychiatric disorders are less likely to discontinue HAART. AIDS 2009;23:1735-1742.
26. Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a ran-domized controlled trial of directly administered anti-retroviral therapy. AIDS Care 2009;21:976-983.
27. Leserman J, Jackson ED, Petitto JM, et al. Progression to AIDS: The effects of stress, depressive symptoms, and social support. Psychosom Med 1999;61:397-406. (Pubitemid 29249799)
28. Krieger N. Overcoming the absence of socioeconomic data in medical records: Validation and application of a census-based methodology. Am J Public Health. 1992;82:703-710.
29. Chi FW, Satre DD, Weisner C. Chemical dependency patients with cooccurring psychiatric diagnoses: Service patterns and 1-year outcomes. Alcohol Clin Exp Res. 2006; 30:851-859.
30. Mertens JR, Lu YW, Parthasarathy S, Moore C, Weisner CM. Medical and psychiatric conditions of alcohol and drug treatment patients in an HMO: Comparison with matched controls. Arch Intern Med. 2003;163:2511-2517. (Pubitemid 37385795)
31. Himelhoch S, Moore RD, Treisman G, Gebo KA. Does the presence of a current psychiatric disorder in AIDS patients affect the initiation of antiretroviral treatment and duration of therapy? J Acquir Immune Defic Syndr 2004;37:1457-1463.
32. Miranda J, Cooper LA Disparities in care for depression among primary care patients. J Gen Intern Med 2004;19:120-126. (Pubitemid 38368460)
33. Heflinger CA, Chatman J, Saunders RC. Racial and gender differences in utilization of Medicaid substance abuse ser-vices among adolescents. Psychiatr Serv 2006;57:504-511.
34. Mertens JR, Weisner C, Ray GT, Fireman B, Walsh K. Ha-zardous drinkers and drug users in HMO primary care: Prevalence, medical conditions, and costs. Alcohol Clin Exp Res 2005;29:989-998. (Pubitemid 40934203)
35. Ray GT, Mertens JR, Weisner C. The excess medical cost and health problems of family members of persons diagnosed with alcohol or drug problems. Med Care 2007;45:116-122.
36. Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. In-tegrating primary medical care with addiction treatment: A randomized controlled trial. JAMA 2001;286:1715-1723. (Pubitemid 33010257)
37. Fairley CK, Permana A, Read TR. Long-term utility of measuring adherence by self-report compared with phar-macy record in a routine clinic setting. HIV Medicine 2005 Sep;6(5):366-9. (Pubitemid 41335147)
38. Satre DD, Campbell CI, Gordon NS, Weisner C. Ethnic disparities in accessing treatment for depression and sub-stance use disorders in an integrated health plan. Int J Psy-chiatry Med 2010;40:57-76.
39. Hartzell JD, Janke IE, Weintrob AC Impact of depression on HIV outcomes in the HAART era. J Antimicrob Chemother 2008;62:246-255.
40. Leserman J. Role of depression, stress, and trauma in HIV disease progression. Psychosom Med 2008;70:539-545.
41. Lima VD, Geller J, Bangsberg DR, et al. The effect of ad-herence on the association between depressive symptoms and mortality among HIV-infected individuals first initiat-ing HAART. AIDS 2007;21:1175-1183. (Pubitemid 46763288)
42. Burnam MA, Bing EG, Morton SC, et al. Use of mental health and substance abuse treatment services among adults with HIV in the United States. Arch Gen Psychiatry 2001;58: 729-736. (Pubitemid 32717796)
43. Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Sub-stance abuse treatment and hospitalization among a cohort of HIV-infected individuals with alcohol problems. Alcohol Clin Exp Res 2005;29:389-394. (Pubitemid 40446131)